Language Selector:

Lungpacer Medical, Inc. Announces Enrollment of First Subject in RESCUE 1 Feasibility Study

BURNABY, British Columbia, 20 June 2017 Lungpacer Medical, Inc., announced today that the first subject has been enrolled in the RESCUE 1 study at the University of Texas Southwestern Medical Center, in Dallas, Texas. This early feasibility study will investigate the safety and feasibility of the Lungpacer Diaphragm Pacing Therapy System (DPTS) as a therapy to […]

Lungpacer Medical, Inc. Announces Publication of Preclinical Findings in American Journal of Respiratory and Critical Care Medicine

BURNABY, British Columbia, February 2017 Lungpacer Medical, Inc., announced today that the findings from preclinical work have been published in the American Journal of Respiratory and Critical Care Medicine: Mitigation of Ventilator-Induced Diaphragm Atrophy by Transvenous Phrenic Nerve Stimulation, Reynolds, S. et al. These findings demonstrate that transvenous phrenic nerve stimulation has the potential to mitigate […]

Lungpacer Medical, Inc. Announces the Completion of First-In-Human Early Feasibility Study

BURNABY, British Columbia, May 2016 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today their completion of the enrollment into the Phrenic ACtivation for Enhanced Respiration (PACER) early feasibility study conducted in Paraguay. The study enrolled a total of 28 subjects and showed that stimulation of the phrenic nerves, […]

Lungpacer Medical, Inc. Presents at 2016 Innovation Summit, April 2016, Dublin, Ireland

Lungpacer Medical, Inc. was invited to present at the 2016 Innovation Summit in Dublin, Ireland, the leading medical technology investment forum in Europe. The Innovation Summit brings together more than 500 leading experts, innovators and key decision-makers to discuss the critical challenges facing the ever-evolving global medical device community. Lungpacer Medical CEO, Doug Evans, presented […]